Pfizer Inc. (PFE) shares are currently trading at $24.20, marking a 1.07% increase from the previous close. This gain comes as the stock opened at $24.27 and saw an intraday range between $23.97 and $24.30, with a trading volume reaching over 41 million shares.
Pfizer's financial performance has shown promising signs, with a 2.1% revenue increase in the second quarter of 2024. Excluding COVID-19 vaccine sales, revenue growth stood at 14%. This is supported by a strong cash reserve of over $10 billion, providing room for sustaining dividends and supporting potential share buybacks. Pfizer's forward P/E ratio of 11.8 and a significant dividend yield of around 6% highlight its valuation appeal, Reuters reported.
The pharmaceutical giant's future growth is supported by a substantial pipeline of 113 drug candidates and strategic expansions such as the $43 billion acquisition of Seagen, enhancing its oncology capabilities. However, challenges persist with investor concerns on return on capital, which has decreased significantly, and skepticism about Pfizer's post-pandemic strategy.